Parametric Portfolio Associates LLC boosted its position in shares of Lipocine Inc. (NASDAQ:LPCN) by 27.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,739 shares of the specialty pharmaceutical company’s stock after buying an additional 12,518 shares during the period. Parametric Portfolio Associates LLC owned approximately 0.32% of Lipocine worth $229,000 as of its most recent SEC filing.

Separately, Ameriprise Financial Inc. raised its stake in shares of Lipocine by 99.4% in the first quarter. Ameriprise Financial Inc. now owns 131,600 shares of the specialty pharmaceutical company’s stock worth $513,000 after buying an additional 65,600 shares in the last quarter. 38.88% of the stock is currently owned by institutional investors.

Shares of Lipocine Inc. (LPCN) opened at 4.42 on Monday. The stock’s market cap is $85.13 million. Lipocine Inc. has a 12 month low of $3.03 and a 12 month high of $5.90. The company has a 50-day moving average price of $4.36 and a 200-day moving average price of $3.96.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. On average, analysts expect that Lipocine Inc. will post ($1.12) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Parametric Portfolio Associates LLC Purchases 12,518 Shares of Lipocine Inc. (NASDAQ:LPCN)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at

A number of equities research analysts recently commented on LPCN shares. Roth Capital set a $38.00 target price on Lipocine and gave the company a “buy” rating in a research report on Tuesday, June 20th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Lipocine in a research report on Wednesday, April 26th. Finally, Canaccord Genuity set a $10.00 target price on Lipocine and gave the company a “buy” rating in a research report on Monday, April 24th.

About Lipocine

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Institutional Ownership by Quarter for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with's FREE daily email newsletter.